Novartis Gets European Approval For Tabrecta To Treat Metex14 Skipping Advanced Non-Small Cell Lung Cancer
Novartis Announced That The European Commission (Ec) Approved Tabrecta (Capmatinib) As A Monotherapy For The Treatment Of Adults With Advanced Non-Small Cell Lung Cancer (Nsclc) Harbouring Alterations Leading To Mesenchymal-Epithelial-Transition Factor Gene (Met) Exon 14 (Metex14) Skipping Who Require Systemic Therapy Following Prior Treatment With Immunotherapy And/Or Platinum-Based Chemotherapy.The Approval Follows A Positive Opinion Issued In April By The Committee For Medicinal Products For Human Use (Chmp) Of The European Medicines Agency (Ema) And Is Applicable To All 27 European Union Member States Plus Iceland, Norway And Liechtenstein.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
